Home | Welcome to Contract Pharma   
Last Updated Saturday, May 23 2015


Financial Report: Amgen

By Kristin Brooks

Published January 29, 2014

4Q Revenues: $5.0 billion (+13%)

4Q Earnings: $1.0 billion (+30%)

FY Revenues: $18.7 billion (+8%)

FY Earnings: $5.1 billion (+17%)

Comments: Total product sales increased 11% in the quarter to $4.8 billion. Combined Neulastaand NEUPOGEN sales were up 8% in the quarter to $1.4 billion. Enbrel sales were up 3% to $1.2 billion. Aranesp sales decreased 4% to $470 million in the quarter, due to lower demand. EPOGEN sales increased 10% to $525 million. Sensipar/Mimparasales increased 20% to $307 million. XGEVA/ Prolia sales increased 41% to $522 million. R&D expenses were up 27% in the quarter to $1.2 billion. The fourth quarter includes results for Onyx Pharmaceuticals, acquired in October 2013.

blog comments powered by Disqus

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On